BASEL LIFE 2018

11–14 September 2018

Congress Center Basel
Switzerland

Genome editing

Genome editing (CRISPR/Cas9) in drug discovery

Date

Thursday, 13 September 2018

Chairs

Claas Aiko Meyer (Roche, Basel, Switzerland)
Filip Roudnicky (Roche, Basel, Switzerland)

Abstract

Genome editing technologies allow engineering parts of the genome by removing, adding or altering sections of the DNA Sequence. Recent discovery of the CRISPR/Cas9 system as a technology for genome editing, enables the simplest, quickest and most versatile way of genome editing. CRISPR/Cas9 technology is quickly developing and has already found many applications as a drug discovery tool and even as a potential new therapeutic agent in cellular and gene therapy. This forum focuses on relevant applications of CRISPR/Cas9 for drug discovery such as identification of novel targets through genetic screens, generation of relevant genetic disease models (human cells or animal models) for validation of drug targets and for mechanistic and safety studies. Importantly, current standard practices and perspectives of genome editing in drug discovery will be presented. Furthermore, the forum will show novel applications and discuss future challenges and potential pitfalls of the technology.

Main sponsor(s)

Sponsor(s)

Supporter(s)